ValenzaBio Revenue and Competitors
Estimated Revenue & Valuation
- ValenzaBio's estimated annual revenue is currently $387.5k per year.
- ValenzaBio's estimated revenue per employee is $77,500
- ValenzaBio's total funding is $93.9M.
Employee Data
- ValenzaBio has 5 Employees.
- ValenzaBio grew their employee count by -44% last year.
ValenzaBio's People
| Name | Title | Email/Phone |
|---|
ValenzaBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 15 | -32% | N/A | N/A |
#10 | $10.1M | 48 | -9% | N/A | N/A |
What Is ValenzaBio?
$93.9M
Total Funding
5
Number of Employees
$387.5k
Revenue (est)
-44%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ValenzaBio News
2022-03-30 - ValenzaBio Announces FDA Clearance of Investigational New ...
ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 5 | -29% | $36M |
#2 | $0.1M | 5 | -29% | $12M |
#3 | $0.5M | 5 | -17% | $76.7M |
#4 | $0.7M | 5 | N/A | N/A |
#5 | $0.3M | 5 | 0% | N/A |